Full Press Release Details
Lexaria Announces Upcoming Public Events and Warrant
Kelowna, British Columbia September 22, 2017 Lexaria
Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) announces
it will be attending and delivering a presentation at the upcoming Canadian
Securities Exchange sponsored Cannabis in the Capital Markets event on
September 27 located in Kelowna, British Columbia. Also presenting at the event
will be Dr. Philip Ainsle, Co-Director of the Centre for Heart, Lung and
Vascular Health, UBC Okanagan Campus, Kelowna, Canada, who will be Principal
Investigator of the previously announce clinical study to be conducted by UBC
and Lexaria. More information on the event can be found here.
Lexaria will also be attending and speaking at the Southwest
Cannabis Conference and Expo in Phoenix, AZ on October 13 and 14. This B2B event
is expected to attract thousands of attendees and more information can be found
Separately Lexaria announced it has received US$93,750from the exercise of warrants previously granted. The stock warrants were
exercised at the price of US$0.15, for a total of 625,000 common shares being
issued. The warrants are being exercised by a third party who is neither an
officer nor director of the Company.
Following issuance of these common shares, Lexaria will have
68,600,761 common shares issued and outstanding. No commissions or placement
fees have been paid related to the funds received from these warrants exercised.
Proceeds will be used for general corporate purposes.The securities referred
to herein will not be or have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold in the United
States absent registration or an applicable exemption from registration
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive technology that promotes healthier ingestion
methods, lower overall dosing and higher effectiveness of lipophilic active
molecules. Lexaria has multiple patents pending in over 40 countries around the
world and was granted its first patents in the USA and in Australia related to
edible forms of cannabinoids. Lexaria s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules.
For regular updates,
connect with Lexaria:
FOR FURTHER INFORMATION PLEASE CONTACT:
Alex Blanchard, Communications Manager
NetworkNewsWire (NNW)
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexaria s
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). Lexaria
Energy Foods, Ambarii, and ViPovaTM products are not intended to
diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.
bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
For regular updates, connect with
FOR FURTHER INFORMATION PLEASE CONTACT:
Alex Blanchard, Communications Manager
NetworkNewsWire (NNW)
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining